Quanterix enters the second half as a Billerica biomarker company that has already spent the Akoya cash and is now trying to sell its way out of a tools slump. The June quarter did not merely miss an internal target. It forced management to cut full-year revenue, push cash-flow breakeven into next year, and write off the leftover goodwill from the spatial acquisition. The investment debate is no longer whether the deal created a broader proteomics platform. It is whether new commercial leadership can stabilize instrument and consumable demand while LucentAD Complete converts reimbursement into a real diagnostics line before cash falls through the year-end floor. Reported sales reached almost $33 million, a gain that disappears once Akoya is put into the year-ago base.
The like-for-like decline ran about 23 percent. Full-year sales guidance now sits between $142 million and $148 million. Prior commentary had pointed toward a band near $170 million. Cash including securities ended the quarter near $97 million. Adjusted cash use slowed to $4 million after integration items. Those figures describe a company that can still fund a reset, not a company that has already earned one.
A $27 million goodwill charge closed the Akoya accounting story. Diagnostics partner sales were only about $2 million, even as Anthem began covering LucentAD Complete and Medicare already prices the multi-marker test at $897. The next several quarters resolve a single commercial question for holders. Does the sales reorganization lift sequential tools revenue and LucentAD volume enough to hold year-end cash near the new $80 million target, or does the franchise keep shrinking until a raise becomes the cleaner path?